Art

J-GLOBAL ID：201402218074887438   Reference number：14A0552459

Linezolid Minimum Inhibitory Concentration (MIC) Creep in Methicillin-Resistant Staphylococcus aureus (MRSA) Clinical Isolates at a Single Japanese Center

日本の1施設におけるメチシリン耐性Staphylococcus aureus(MRSA)臨床分離株でのリネゾリドの最小発育阻止濃度(MIC)creep

Author (7)： MIYAZAKI Motoyasu (Dep. of Pharmacy, Fukuoka Univ. Chikushi Hospital) ,  NAGATA Nobuhiko (Dep. of Respiratory Medicine, Fukuoka Univ. Chikushi Hospital) ,  MIYAZAKI Hiroyuki (Dep. of Respiratory Medicine, Fukuoka Univ. Chikushi Hospital) ,  MATSUO Koichi (Dep. of Pharmacy, Fukuoka Univ. Chikushi Hospital) ,  TAKATA Tohru (Dep. of Infection Control, Fukuoka Univ. Hospital) ,  TANIHARA Shinichi (Dep. of Preventive Medicine and Public Health, School of Medicine, Fukuoka Univ.) ,  KAMIMURA Hidetoshi (Dep. of Pharmacy, Fukuoka Univ. Chikushi Hospital)
Material： Biological and Pharmaceutical Bulletin  (Biological & Pharmaceutical Bulletin)
Volume： 37  Issue： 4  Page： 679-682 (J-STAGE)  Publication year： 2014 
JST Material Number： S0989A  ISSN： 0918-6158  CODEN： BPBLEO  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： human(primates) ,...
Semi thesaurus term： MSSA ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=14A0552459&from=J-GLOBAL&jstjournalNo=S0989A") }}

JST classification (2)： Clinical application of antibacterial drugs  (GW17030D) ,  Infectious diseases,parasitics diseases in general.  (GD01010H)

Substance index (1)： Linezolid

Reference (12)：

• 1) Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann. Intern. Med., 138, 135-142 (2003).
• 2) Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L, Moellering RC Jr, Ferraro MJ. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet, 358, 207-208 (2001).
• 3) Jones RN, Kohno S, Ono Y, Ross JE, Yanagihara K. ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countries. Diagn. Microbiol. Infect. Dis., 64, 191-201 (2009).
• 4) Clinical and Laboratory Standards Institute (CLSI). Performance standard for antimicrobial susceptibility testing; twentieth informational supplement. Document M100-S20. CLSI, Wayne, PA (2010).
• 5) Yoshida K, Shoji H, Hanaki H, Yanagisawa C, Ikeda-Dantsuji Y, Fukuchi K, Adachi M, Niki Y. Linezolid-resistant methicillin-resistant Staphylococcus aureus isolated after long-term, repeated use of linezolid. J. Infect. Chemother., 15, 417-419 (2009).

Terms in the title (9)： 日本 ,  施設 ,  メチシリン耐性 ,  Staphylococcus ,  MRSA ,  臨床分離株 ,  リネゾリド ,  最小発育阻止濃度 ,  MIC